66. IgA nephropathy Clinical trials / Disease details

Clinical trials : 255 / Drugs : 255 - (DrugBank : 79) / Drug target genes : 35 - Drug target pathways : 137

diseases per page:

Showing 1 to 10 of 255 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05174221 (ClinicalTrials.gov)	May 30, 2022	14/12/2021	A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Backgrou ...	A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Ef ...	Kidney Disease	Drug: Mezagitamab	Takeda	NULL	Not yet recruiting	18 Years	N/A	All	16	Phase 1	NULL
2	NCT05125068 (ClinicalTrials.gov)	February 28, 2022	8/11/2021	Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)	A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients ...	IgA Nephropathy;IgAN	Drug: AT-1501	Eledon Pharmaceuticals	NULL	Not yet recruiting	18 Years	99 Years	All	42	Phase 2	NULL
3	NCT05083364 (ClinicalTrials.gov)	February 2, 2022	8/10/2021	Study of ARO-C3 in Adult Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria an ...	A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Ph ...	Paroxysmal Nocturnal Hemoglobinuria;C3 Glomerulopathy;IgA Nephropathy	Drug: ARO-C3;Drug: Placebo	Arrowhead Pharmaceuticals	NULL	Recruiting	18 Years	70 Years	All	62	Phase 1	New Zealand
4	EUCTR2020-002200-40-DK (EUCTR)	11/01/2022	02/07/2021	A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label i ...	A multicenter rollover extension program (REP) to evaluate the long-term safety and tolerability of ...	IgA Nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;Sy ...	Product Name: iptacopan Product Code: LNP023 INN or Proposed INN: iptacopan Other descriptive name: LN ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	427	Phase 3	United States;Hong Kong;Taiwan;Spain;Thailand;Israel;Russian Federation;Colombia;Italy;India;Vietnam ...
5	EUCTR2021-000621-27-IT (EUCTR)	11/01/2022	12/10/2021	Safety, efficacy and pharmacokinetics of sparsentan in pediatric subjects with selected kidney disea ...	A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokineti ...	Proteinuric glomerular diseases including:•Focal segmental glomerulosclerosis (FSGS) •Minimal change ...	Product Name: Sparsentan Product Code: [RE-021] INN or Proposed INN: Sparsentan	TRAVERE THERAPEUTICS, INC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	57	Phase 2	France;United States;Spain;Poland;Netherlands;Germany;United Kingdom;Italy;Sweden
6	EUCTR2020-003084-26-CZ (EUCTR)	24/11/2021	13/07/2021	A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nep ...	A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nep ...	Immunoglobulin A Nephropathy (IgAN);Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: atrasentan INN or Proposed INN: atrasentan Other descriptive name: ATRASENTAN	Chinook Therapeutics U.S., Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	320	Phase 3	United States;Portugal;Czechia;Taiwan;Hong Kong;Spain;Ireland;Colombia;United Kingdom;Italy;India;Fr ...
7	EUCTR2020-004892-41-DE (EUCTR)	16/11/2021	09/06/2021	Atacicept in Subjects with IgA Nephropathy (ORIGIN)	A Phase IIb Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Effic ...	IgA Nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;Sy ...	Product Name: Atacicept Product Code: VT-001 INN or Proposed INN: Atacicept Other descriptive name: ATA ...	Vera Therapeutics, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	105	Phase 2	Belarus;United States;Czechia;Greece;Turkey;United Kingdom;India;Czech Republic;Canada;Malaysia;Belg ...
8	NCT04905212 (ClinicalTrials.gov)	November 4, 2021	21/5/2021	A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy	A Phase 2, Randomized, Double-Blind, Multicenter Study of Telitacicept for Injection (RC18) in Subje ...	IgA Nephropathy	Drug: Telitacicept 160mg;Drug: Telitacicept 240mg;Drug: Placebo	RemeGen Co., Ltd.	NULL	Recruiting	18 Years	70 Years	All	30	Phase 2	United States
9	EUCTR2020-002200-40-NO (EUCTR)	14/10/2021	26/08/2021	A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label i ...	A multicenter rollover extension program (REP) to evaluate the long-term safety and tolerability of ...	IgA Nephropathy MedDRA version: 20.0;Level: PT;Classification code 10021263;Term: IgA nephropathy;Sy ...	Product Name: iptacopan Product Code: LNP023 INN or Proposed INN: iptacopan Other descriptive name: LN ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	427	Phase 3	Malaysia;Australia;Denmark;Netherlands;China;Korea, Republic of;Czechia;Finland;Turkey;United Kingdo ...
10	EUCTR2018-000075-33-GR (EUCTR)	13/10/2021	13/07/2021	OMS721 in patients with IgA Nephropathy (ARTEMIS-IGAN)	A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 i ...	IgA nephropathy(IgAN) MedDRA version: 20.1;Level: PT;Classification code 10029151;Term: Nephropathy; ...	Product Code: OMS721 INN or Proposed INN: OMS721 Other descriptive name: OMS721	Omeros Corporation	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	450	Phase 3	United States;Taiwan;Slovakia;Greece;Thailand;Spain;Italy;Australia;China;Korea, Republic of;Czechia ...

First Previous1 2 3 4 5…26Next Last